Mail

TRHC - Tabula Rasa HealthCare, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

49.69

-4.40 (-8.13%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	54.09
Open	54.53
Bid	0.00 x 800
Ask	0.00 x 800
Day's Range	48.57 - 54.53
52 Week Range	39.06 - 91.16
Volume	761,144
Avg. Volume	430,119

Market Cap	1.08B
Beta (3Y Monthly)	1.62
PE Ratio (TTM)	N/A
EPS (TTM)	-2.48
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	83.50

Trade prices are not sourced from all markets

All

News

Press Releases

Zacks3 days ago
S&P Approaches New Highs After Crossing Above 2900
S&P; Approaches New Highs After Crossing Above 2900
GlobeNewswire6 days ago
AMAG Pharmaceuticals Appoints New Members to Board of Directors
“We are pleased to welcome Dr. Phillips and Ms. O’Brien to AMAG’s board,” said Gino Santini, chairman of the board of AMAG. “As AMAG continues to invest and focus on the development and commercialization of novel pharmaceutical products that address unmet medical needs, the deep experience and expertise that Dr. Phillips and Ms. O’Brien each bring will be invaluable to AMAG.
GlobeNewswire7 days ago
Prominent Arkansas Health Plan Partners with Tabula Rasa Healthcare’s PrescribeWellness to Improve Quality & Performance Outcomes for its Members
Tabula Rasa HealthCare, Inc. (TRHC) (TRHC), a healthcare technology company advancing the field of medication safety, today announced it has contracted with one of the largest health insurers in Arkansas. The partnership, through TRHC’s PrescribeWellness subsidiary, will improve quality and performance outcomes for eligible plan members who fit criteria by leveraging community pharmacists to improve medication adherence and address gaps in care.
Zacks9 days ago
CERN or TRHC: Which Is the Better Value Stock Right Now?
CERN vs. TRHC: Which Stock Is the Better Value Option?
GlobeNewswire13 days ago
Tabula Rasa HealthCare’s DoseMe executes first-ever integration of its Precision Dosing Software with market-leading Electronic Medical Record provider
Tabula Rasa HealthCare, Inc. (TRHC) (TRHC), a healthcare technology company advancing the field of medication safety, today announced that its newly-acquired precision dosing software company DoseMe completed the country’s first fully-integrated Precision Dosing Software solution for one of the nation’s leading health care providers with multiple locations in Florida. “We are pleased with the traction our recently-acquired DoseMeRx is garnering in the United States in helping patients with precision, parenteral pharmacotherapy,” said TRHC Chairman and CEO Calvin H. Knowlton, PhD.
GlobeNewswire15 days ago
Tabula Rasa HealthCare Participates in NPA’s Spring Policy Forum
MOORESTOWN, N.J., April 03, 2019 -- Tabula Rasa HealthCare, Inc. (“TRHC”) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety and improving.
GlobeNewswire28 days ago
Tabula Rasa HealthCare Co-Founder and President to Receive Fellow Award from the American Pharmacists Association
MOORESTOWN, N.J., March 21, 2019 -- Tabula Rasa HealthCare, Inc. (TRHC) (NASDAQ: TRHC) President Orsula V. Knowlton, PharmD, MBA, will be named a Fellow of the American.
GlobeNewswirelast month
Tabula Rasa HealthCare’s SinfoníaRx Publishes Comprehensive 2019 Medication Therapy Management Program Performance Report
MOORESTOWN, N.J., March 19, 2019 -- Tabula Rasa HealthCare, Inc. (“TRHC”) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, today.
GlobeNewswirelast month
Tabula Rasa HealthCare Chief Strategic Growth Officer to Present at Innovation Showcase
“Advancing Value through the Science of Personalized Medication Management” MOORESTOWN, N.J., March 18, 2019 -- Tabula Rasa HealthCare, Inc. (NASDAQ: TRHC) Chief Strategic.
American City Business Journalslast month
Tabula Rasa CEO said his company is done making acquisitions, for now
South Jersey medical technology company Tabula Rasa culminated an active shopping spree last week with its fifth acquisition in less than two years. The company, which helps health care providers manage medication risk and prevent adverse drug reactions, paid $150 million for PrescribeWellness. California-based PrescribeWellness is the developer of software used by community pharmacies to predict and better manage work flow.
Simply Wall St.last month
Should You Think About Buying Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) Now?
Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), which is in the healthcare services business, and is based in United States, saw a double-digit share price rise of over 10% in the pastRead More...
GlobeNewswirelast month
Tabula Rasa HealthCare to Participate in Upcoming Investor Conference
MOORESTOWN, N.J., March 08, 2019 -- Tabula Rasa HealthCare, Inc. (“TRHC”) (NASDAQ:TRHC), a healthcare technology company advancing the field of medication safety, today.
American City Business Journalslast month
Tabula Rasa acquires pharmacy software firm for $150M
The deal will bring Tabula Rasa's medication risk mitigation technology to more community pharmacies.
GlobeNewswirelast month
Tabula Rasa HealthCare Appoints New Member to its Board of Directors
MOORESTOWN, N.J., March 06, 2019 -- Tabula Rasa HealthCare, Inc. (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, appointed former.
GlobeNewswirelast month
Tabula Rasa HealthCare Announces Acquisition of PrescribeWellness Expanding its Medication Risk Mitigation Offering
Tabula Rasa HealthCare, Inc. (“TRHC”) (TRHC), a healthcare technology company advancing the field of medication safety, today announced that it has acquired PrescribeWellness (“PW”), a leading cloud-based patient relationship management solutions company that facilitates collaboration between more than 10,000 pharmacies with patients, payers, providers and pharmaceutical companies. This acquisition supports TRHC’s goals of expanding medication risk mitigation programs in community pharmacies and providing community pharmacists with clinical revenue opportunities beyond dispensing. It also enables TRHC to further participate in Medicare Part D Medication Therapy Management programs, and other similar programs, which require or can benefit from the involvement of community pharmacies. Participation in these programs will allow TRHC to generate revenue from channels that were not previously accessible to TRHC. PW generated revenue of $29.0 million in 2018 and ended the year with annual recurring revenue of $32.0 million.
Motley Fool2 months ago
Tabula Rasa HealthCare, Inc. (TRHC) Q4 2018 Earnings Conference Call Transcript
TRHC earnings call for the period ending December 31, 2018.
GlobeNewswire2 months ago
Tabula Rasa HealthCare Announces Fourth Quarter and Full Year 2018 Operating Results
2018 Revenue of $204.3 million, growth of 53%; 4Q 2018 Revenue of $57.3 million, growth of 32%Provides initial 2019 financial outlook MOORESTOWN, N.J., Feb. 28, 2019 -- Tabula.
GlobeNewswire2 months ago
CEO of TRHC’s New Research & Development Institute to Present at National University of Singapore
Tabula Rasa HealthCare, Inc. (TRHC) (TRHC), a healthcare technology company advancing the field of medication safety, today announced that TRHC’s Chief Scientific Officer and CEO of TRHC’s Scientific Precision Pharmacotherapy Research & Development Institute, Jacques Turgeon, BPharm, PhD, will present at the National University of Singapore’s “Healthcare in the Era of Big Data and AI” workshop on Thursday, February 28, 2019. Dr. Turgeon will detail how TRHC’s clinical decision support system harnesses big data and science, including evidence-based clinical data, patient-specific data and pharmacogenetics, to rapidly assess and prevent medication risks. This approach has been used to establish the risk of medication-related adverse effects – and their association with medical expenditures – in more than 1.5 million patients.
GlobeNewswire2 months ago
New Research Coverage Highlights Avis Budget Group, Genesis Energy, Columbia Property Trust, Westlake Chemical, Tabula Rasa Healthcare, and ACM Research — Consolidated Revenues, Company Growth, and Expectations for 2019
NEW YORK, Feb. 22, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
GlobeNewswire2 months ago
Tabula Rasa HealthCare Announces Launch and Location of New Scientific Precision Pharmacotherapy Research & Development Institute
Tabula Rasa HealthCare, Inc. (TRHC) (TRHC), a healthcare technology company advancing the field of medication safety, today announced the launch of its Scientific Precision Pharmacotherapy Research and Development Institute. The Institute is based within Lake Nona Medical City in Orlando. TRHC’s Scientific Precision Pharmacotherapy Research & Development Institute is committed to the development of proprietary products for optimizing medication regimens to improve patient outcomes, reduce utilization of healthcare services, lower healthcare costs, and manage risk.
Zacks2 months ago
Tabula Rasa Healthcare (TRHC) Reports Next Week: Wall Street Expects Earnings Growth
Tabula Rasa Healthcare (TRHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GlobeNewswire2 months ago
Tabula Rasa HealthCare Expands MTM Software Reach outside the United States through a License to a Canadian Pharmacy Organization Focused on Enhancing Health Outcomes
Tabula Rasa HealthCare, Inc. (“TRHC”) (TRHC), a healthcare technology company advancing the field of medication safety, and Canada based Remedy Holdings, Inc. (RHI), a company with a specialty pharmacy network across Canada, today announced an agreement that brings TRHC’s Medication Therapy Management (MTM) technology to Canadian citizens. RHI, under its innovation division HumanisRx, will license RxCompanion™, TRHC’s MTM technology, as a service offering.
GlobeNewswire2 months ago
Tabula Rasa HealthCare Announces Closing of Offering of 1.75% Convertible Notes and Exercise in Full of Option to Purchase Additional Notes
Tabula Rasa HealthCare, Inc. (TRHC) (“TRHC”) today announced the closing of its previously announced offering of $325 million principal amount of 1.75% convertible senior subordinated notes due 2026 (the “notes”), including the exercise by the initial purchasers of their option to purchase an additional $40 million principal amount of the notes, solely to cover over-allotments. The notes are convertible, at the holder’s option, at an initial conversion rate of 14.2966 shares of TRHC’s common stock per $1,000 principal amount of notes, subject to adjustment in certain circumstances. This conversion rate is equal to an initial conversion price of approximately $69.95 per share.
GlobeNewswire2 months ago
Tabula Rasa Healthcare to Announce Fourth Quarter and Full Year 2018 Operating Results and Host Conference Call on Thursday, February 28, 2019
MOORESTOWN, N.J., Feb. 11, 2019 -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), a healthcare technology company advancing the field of medication safety, will release its fourth.
GlobeNewswire2 months ago
Tabula Rasa HealthCare Announces Pricing of $285 Million of 1.75% Convertible Notes
Tabula Rasa HealthCare, Inc. (TRHC) (“TRHC”) today announced the pricing of $285 million principal amount of 1.75% convertible senior subordinated notes due 2026 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Act”). TRHC has also granted the initial purchasers of the notes an option to purchase, within a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $40 million principal amount of the notes, solely to cover over-allotments, if any. The notes are convertible, at the holder’s option, at an initial conversion rate of 14.2966 shares of TRHC’s common stock per $1,000 principal amount of notes, subject to adjustment in certain circumstances.